Navigation Links
InfraReDx Announces Presentation of LipiScan™ Research at American Heart Association Scientific Sessions 2010
Date:11/12/2010

BURLINGTON, Mass., Nov. 12, 2010 /PRNewswire/ -- InfraReDx, Inc., a medical device company developing intelligent cardiovascular diagnostic imaging technologies, today announced the upcoming presentation of three LipiScan™-related scientific abstracts at the American Heart Association Scientific Sessions 2010 (AHA 2010), being held Nov. 13-17, 2010 at McCormick Place in Chicago. The research being presented includes an oral abstract session focused on cost effectiveness and screening advances, as well as two abstract poster sessions involving InfraReDx's research in the area of lipid core plaque burden and its role in coronary health. Additionally, the company will be exhibiting at booth #950 on Nov. 14-16.

InfraReDx recently launched the LipiScan IVUS Coronary Imaging System, the world's first and only intravascular imaging system that combines and co-registers grayscale intravascular ultrasound (IVUS) with the company's proprietary near infrared (NIR) spectroscopy lipid core plaque (LCP) detection technology, to improve the safety and effectiveness of stenting procedures.

"The role of lipid core plaque in coronary artery disease continues to be a topic of significant medical interest as indicated by the AHA meeting program," said James E. Muller, M.D., founder and chief executive officer of InfraReDx. "We are pleased that the LipiScan IVUS system is now available for use by the cardiology community. The LipiScan component of the multimodality catheter provides a rapid and accurate means to identify lipid core plaque in patients undergoing catheterization. Detection of these plaques is of clinical importance because there is extensive evidence indicating that these lipid core plaques are 'complication-prone' when stenting is performed. In addition, lipid core plaques are suspected to be 'vulnerable plaques' that cause spontaneous coronary events occurring in the community."

The three abstracts being presented per the schedule below highlight different aspects of the pathophysiology of coronary artery disease:

  • Abstract poster session (APS.606.02), "Investigating Culprit Coronary Artery Plaques," Monday, Nov. 15, from 9 a.m. to 5 p.m. in Hall A2, Core 6.
  • The relevant presentation (18425), "Intracoronary Lipid Burden in Diabetic Patients Undergoing Percutaneous Coronary Intervention (PCI); Results from the COLOR Registry," will be on display with Daniel H. Steinberg, M.D., of the Medical University of South Carolina in Charleston available as a discussant from 9:30 to 11 a.m.

  • Steinberg et al. report the frequency of lipid core plaque in coronary patients with and without diabetes, a condition associated with an increased frequency of coronary disease.

  • Abstract poster session (APS.606.01), "Coronary Pathophysiology Assessment in the Catheterization Lab," Tuesday, Nov. 16, from 9 a.m. to 5 p.m. in Hall A2, Core 6.
  • The relevant presentation (21455), "Histopathologic Validation of Intravascular Ultrasound Diagnosis of a Calcified Coronary Nodule, a Type of Plaque Suspected to be Vulnerable," will be on display with Jin Bae Lee, M.D., of the Cardiovascular Research Foundation and Columbia University Medical Center in New York available as a discussant from 3 to 4:30 p.m.

  • Lee et al. describe IVUS and spectroscopy features of a special type of plaque -- a calcified nodule -- that is suspected to be an unusual cause of heart attacks.

  • Abstract oral session (AOS.107.03c), "Coronary Computed Tomography: Cost Effectiveness, Screening and Other Big Picture Issues," Tuesday, Nov. 16, from 2 to 5:15 p.m. in Room E271b.  
  • The relevant oral presentation (19352) takes place at 3:35 p.m.; "Features of Plaque Disruption by Coronary CT Angiography are Associated with Lipid Core Plaque by Intracoronary Near-Infrared Spectroscopy," will be presented by Ivan D. Hanson, M.D., of William Beaumont Hospital in Royal Oak, Mich.

  • Hanson et al. present a comparison of signs of lipid core plaque as detected by CTA -- a non-invasive method suitable for a role in a preventive screening strategy -- with the presence of lipid core confirmed by LipiScan IVUS during coronary angiography.

    About LipiScan IVUSThe LipiScan IVUS system employs proprietary optical imaging technology to overcome the challenges of heart motion, blood interference, and vascular access to perform NIR spectroscopic analysis of the vessel and produce a chemical map of lipid-core plaque called a Chemogram™. The system provides physicians with a traditional IVUS image that shows plaque location, degree of stenosis and degree of stent expansion. At the same time, optical data are recorded that permit identification and co-localization of lipid core plaques. This innovative multi-modality analysis is accomplished directly in the catheterization laboratory during the coronary intervention via a single catheter pullback procedure. The data are immediately available to the physician to help guide the stenting procedure.

    About InfraReDx, Inc.InfraReDx, Inc. is a privately funded medical device company improving patient care through the development and commercialization of intelligent imaging technologies to improve the diagnosis and treatment of coronary artery disease. InfraReDx's LipiScan™ IVUS Coronary Imaging System is the first and only available catheter to combine both near-infrared spectroscopy (NIR) and intravascular ultrasound (IVUS) technologies to both visualize and characterize the intracoronary lipid core plaques (LCP) suspected of causing the majority of heart attacks. Founded in 1998, InfraReDx is headquartered in Burlington, Massachusetts. For more information, visit www.infraredx.com.  Contacts:Susan Heins (media)Pure Communications, Inc.864-286-9597sjheins@purecommunicationsinc.comGrant FrazierVice President of MarketingInfraReDx, Inc.781-345-9632gfrazier@infraredx.com
    '/>"/>

    SOURCE InfraReDx, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Related medicine technology :

    1. InfraReDx Completes $21 Million Equity Financing
    2. InfraReDxs New LipiScan™ IVUS Coronary Imaging System to be Highlighted at TCT 2010
    3. InfraReDxs LipiScan(TM) Coronary Imaging System for Identification of Lipid Core Plaque to be Highlighted at 59th Annual Scientific Session of the American College of Cardiology
    4. InfraReDx to Showcase the LipiScan(TM) Coronary Imaging System at the Cardiovascular Research Foundations (CRF) Annual Transcatheter Cardiovascular Therapeutics (TCT) Scientific Meeting
    5. First Use in a Patient of The InfraReDx LipiScan(TM) Coronary Imaging System
    6. FDA Grants Market Clearance for the LipiScan(TM) Coronary Imaging System Developed by InfraReDx, Inc. - A Novel Spectroscopy System for the Identification of Lipid Core Containing Plaques of Interest in the Coronary Arteries
    7. Cardica Announces Fiscal 2011 First Quarter Financial Results
    8. Jazz Pharmaceuticals Announces Presentation at the Lazard Capital Markets Healthcare Conference on November 17
    9. Bionovo Announces Third Quarter 2010 Highlights and Financial Results
    10. Dehaier Medical Announces Conference Call to Discuss Third Quarter 2010 Financial Results
    11. Dynatronics Announces Fiscal First Quarter Results
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:2/5/2016)... , Feb. 5, 2016  Aralez Pharmaceuticals Inc. ... of POZEN Inc. ("POZEN") and Tribute Pharmaceuticals Canada Inc. ("Tribute") ... and shareholders of Tribute. The combined company will operate ... company with operations in Canada , ... United States . Under the terms of the ...
    (Date:2/5/2016)... February 5, 2016 --> ... report states that the global active pharmaceuticals ingredients (APIs) ... predicted to reach US$185.9 bn by 2020. It is ... 2014 to 2020. The title of the report is ... by Geography, and by Therapeutic Area) - Global Industry ...
    (Date:2/5/2016)... Feb. 5, 2016  Henry Schein, Inc. (NASDAQ: HSIC ... and services to office-based dental, animal health and medical ... agreement to acquire a majority ownership interest in Dental ... in Brazil . ... Dental Cremer is the dental distribution business of Cremer ...
    Breaking Medicine Technology:
    (Date:2/5/2016)... ... February 05, 2016 , ... The event is being ... Block Event Center in Minneapolis, Minn. Triumph Over Parkinson’s will fund nearly $100,000 for ... of Schneiderman’s Furniture, lives with Parkinson’s disease and is the architect of this informative ...
    (Date:2/5/2016)... ... , ... After years as an active staff surgeon and having served as ... Wayne Carman transitioned to chief of the Division of Plastic Surgery at what is ... chief and began a second three-year term in January of 2016. , The original ...
    (Date:2/5/2016)... ... February 05, 2016 , ... Regular gym users know ... having to wait longer to access the treadmills. It’s a predictable trend. After the ... lose weight and get in shape by joining gyms, starting new walking or running ...
    (Date:2/5/2016)... Georgia (PRWEB) , ... February 05, 2016 , ... Dr. ... to announce their 2nd Annual No Cost Dental Day to individuals in need. The ... The purpose of this No Cost Dental Day is to provide dental care to ...
    (Date:2/5/2016)... ... February 05, 2016 , ... Health and wellness is a topic that should ... event they are experiencing an illness. Migraines are a severe form of a headache ... migraines would not wish the pain on their worst enemy, the feeling can last ...
    Breaking Medicine News(10 mins):